Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 46 min ago
Peer-reviewedCC BYCancers

Transfer Learning-Based Quantification of Mitotic Activity and Its Prognostic and Molecular Associations in Lung Squamous Cell Carcinoma.

5 affiliations
  1. 1Department of Pulmonology, Bandırma Training and Research Hospital, Bandırma 10200, Türkiye.
  2. 2Institute of Research and Development, Duy Tan University, Da Nang 550000, Vietnam.
  3. 3School of Engineering and Technology, Duy Tan University, Da Nang 550000, Vietnam.
  4. 4Department of Computer Engineering, Bandırma Onyedi Eylül University, Balıkesir 10200, Türkiye.
  5. 5Engineering and Informatics Department, Klaipėdos Valstybinė Kolegija/Higher Education Institution, 92294 Klaipeda, Lithuania.

Abstract

Background: Automated assessment of mitotic activity may provide a reproducible marker of tumor proliferation, but computational mitosis recognition remains challenging because of cross-domain variability. We developed a transfer-learning framework to quantify mitotic activity in lung squamous cell carcinoma (LUSC) and investigated its clinical and molecular associations. Methods: A ResNet-34 classifier was trained using MIDOG source-domain data and adapted to TCGA-LUSC diagnostic whole-slide images. The target cohort included 478 patients and 512 whole-slide images. Tumor regions and mitotic figures were annotated by two pathologists, and 128 × 128-pixel patches at 40× resolution were analyzed. After identifying patient overlap in the initial patch-level partition, we implemented patient-level stratified five-fold cross-validation to obtain leakage-mitigated performance estimates and out-of-fold predictions. Tumor-area mitosis proportion (TAMP) was defined as the proportion of evaluable tumor-region patches classified as mitosis-positive. Prognostic associations were evaluated using multivariable Cox proportional-hazards regression adjusted for age, sex, and pathological stage. Results: The classifier achieved an AUC of 0.972 (95% CI, 0.965-0.980) on the internal MIDOG test set. Direct application to TCGA-LUSC yielded an AUC of 0.81, whereas target-domain fine-tuning produced an initial patch-level AUC of 0.93. Patient tracing identified overlap in the original partitions, with 142 patients (29.7%) contributing patches to multiple subsets, including 67 patients (14.0%) represented in both training and test sets. Leakage-mitigated patient-level cross-validation yielded a mean AUC of 0.88 (95% CI, 0.86-0.90) and PR-AUC of 0.24. A patient-disjoint WSI holdout evaluation yielded an AUC of 0.87 (95% CI, 0.84-0.90) and PR-AUC of 0.22. High TAMP was associated with poorer overall survival (log-rank p=0.017; HR = 1.73, 95% CI, 1.12-2.68) and remained significant after adjustment for age, sex, and pathological stage (adjusted HR = 1.62, 95% CI, 1.03-2.54; p=0.036). High-TAMP tumors showed enrichment of proliferation- and growth-related transcriptional programs, whereas immune, genomic, and predicted drug-response associations were modest and hypothesis-generating. Conclusions: TAMP represents an image-derived measure of mitotic activity associated with survival and molecular characteristics in TCGA-LUSC. The findings support further investigation of computational mitotic phenotyping, but external multicenter validation and prospective clinical assessment are required before clinical translation.

Related

  1. Integrative Multi-Database Bioinformatics Characterization of FANCE in Hepatocellular Carcinoma: Prognostic, Epigenetic, Immune, and ncRNA Associations
    Yeong Chae Kim, Kyu-Shik Lee, Hye-Ran Kim +1
    Medicina (Kaunas, Lithuania)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Radiomics-based machine learning models decipher heterogeneity of anoikis-related molecular subtypes for prognostic stratification in head and neck squamous cell carcinoma
    Linyong Wu, Dayou Wei, Wubiao Chen +4
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. SOLUBLE CELL ADHESION MOLECULES QUANTIFICATION IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: PROGNOSTIC IMPLICATIONS AND CLINICAL-BIOLOGICAL ASSOCIATIONS
    Paola Carolina RABESQUINI MARCELINO DA SILVA, Igor CEREJO TAVARES DA SILVA DE ALMEIDA, Joaquim GASPARINI DOS SANTOS +7
    Hematology, Transfusion and Cell TherapyPeer-reviewedCC BYFull textEndocrinology & metabolismDOAJ
  4. Histology-Stratified Clinical and Prognostic Associations of PDCD-Related Genes in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Seong-Tae Kim, Yunha Lee, Se-Young Yun +8
    GenesPeer-reviewedCC BYFull textOncologyEurope PMC
  5. Integrated Transcriptomic and Regulatory Network Analysis Reveals Distinct Molecular Subtypes with Prognostic Significance in Clear Cell Renal Cell Carcinoma
    Muhammad Ammar Zahid, Walid Kouidri, Abbas Khan +1
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
BibTeX
@article{gunes2026transfer,
  title = {{Transfer Learning-Based Quantification of Mitotic Activity and Its Prognostic and Molecular Associations in Lung Squamous Cell Carcinoma.}},
  author = {Gulcin Yilmaz Gunes and Mehmet Akif Cifci},
  journal = {Cancers},
  year = {2026},
  month = sep,
  doi = {10.3390/cancers18193098},
  url = {https://europepmc.org/article/MED/42882793},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Transfer Learning-Based Quantification of Mitotic Activity and Its Prognostic and Molecular Associations in Lung Squamous Cell Carcinoma.
AU  - Gulcin Yilmaz Gunes
AU  - Mehmet Akif Cifci
PY  - 2026
DA  - 2026/09/23
JO  - Cancers
DO  - 10.3390/cancers18193098
UR  - https://europepmc.org/article/MED/42882793
AB  - Background: Automated assessment of mitotic activity may provide a reproducible marker of tumor proliferation, but computational mitosis recognition remains challenging because of cross-domain variability. We developed a transfer-learning framework to quantify mitotic activity in lung squamous cell carcinoma (LUSC) and investigated its clinical and molecular associations. Methods: A ResNet-34 classifier was trained using MIDOG source-domain data and adapted to TCGA-LUSC diagnostic whole-slide images. The target cohort included 478 patients and 512 whole-slide images. Tumor regions and mitotic figures were annotated by two pathologists, and 128 × 128-pixel patches at 40× resolution were analyzed. After identifying patient overlap in the initial patch-level partition, we implemented patient-level stratified five-fold cross-validation to obtain leakage-mitigated performance estimates and out-of-fold predictions. Tumor-area mitosis proportion (TAMP) was defined as the proportion of evaluable tumor-region patches classified as mitosis-positive. Prognostic associations were evaluated using multivariable Cox proportional-hazards regression adjusted for age, sex, and pathological stage. Results: The classifier achieved an AUC of 0.972 (95% CI, 0.965-0.980) on the internal MIDOG test set. Direct application to TCGA-LUSC yielded an AUC of 0.81, whereas target-domain fine-tuning produced an initial patch-level AUC of 0.93. Patient tracing identified overlap in the original partitions, with 142 patients (29.7%) contributing patches to multiple subsets, including 67 patients (14.0%) represented in both training and test sets. Leakage-mitigated patient-level cross-validation yielded a mean AUC of 0.88 (95% CI, 0.86-0.90) and PR-AUC of 0.24. A patient-disjoint WSI holdout evaluation yielded an AUC of 0.87 (95% CI, 0.84-0.90) and PR-AUC of 0.22. High TAMP was associated with poorer overall survival (log-rank p=0.017; HR = 1.73, 95% CI, 1.12-2.68) and remained significant after adjustment for age, sex, and pathological stage (adjusted HR = 1.62, 95% CI, 1.03-2.54; p=0.036). High-TAMP tumors showed enrichment of proliferation- and growth-related transcriptional programs, whereas immune, genomic, and predicted drug-response associations were modest and hypothesis-generating. Conclusions: TAMP represents an image-derived measure of mitotic activity associated with survival and molecular characteristics in TCGA-LUSC. The findings support further investigation of computational mitotic phenotyping, but external multicenter validation and prospective clinical assessment are required before clinical translation.
SN  - 2072-6694
ER  -